- Companies
- enGene Therapeutics
enGene Therapeutics Valuation Multiples
enGene Therapeutics is valued at $128M as of September 2026. In the last FY enGene Therapeutics reported revenue of - and EBITDA of ($123M).
enGene Therapeutics Overview
About enGene Therapeutics
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Founded
2023
HQ
Employees
82
Website
Financials (FY)
Market Cap
$128M
Valuation Multiples
Start free trialenGene Therapeutics Financials
enGene Therapeutics reported last fiscal year revenue of - and negative EBITDA of ($123M).
In the same fiscal year, enGene Therapeutics generated ($123M) in EBITDA losses and had net loss of ($117M).
Revenue (LTM)
enGene Therapeutics P&L
In the most recent fiscal year, enGene Therapeutics reported revenue of - and EBITDA of ($123M).
enGene Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.
Financial data powered by Morningstar, Inc.
enGene Therapeutics Stock Performance
enGene Therapeutics has current market cap of $128M.
Market Cap Evolution
enGene Therapeutics' stock price is $1.91.
enGene Therapeutics share price decreased by 72.0% in the last year.
enGene Therapeutics has an EPS (earnings per share) of $-1.75.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $128M | 0.3% | - | - | -72.0% | $-1.75 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialenGene Therapeutics Valuation Multiples
enGene Therapeutics Financial Valuation Multiples
As of September 18, 2026, enGene Therapeutics has market cap of $128M.
enGene Therapeutics has a P/E ratio of (1.1x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified enGene Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


enGene Therapeutics Operational KPIs
enGene Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.5M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
enGene Therapeutics Competitors
enGene Therapeutics competitors include Nyrada, Biomea Fusion, Orient Europharma Co, LENZ Therapeutics, Biosyent, vTv Therapeutics, Inovio Pharmaceuticals, BRIM Biotechnology, Naturland Holding and Tiziana Life Sciences.
Most enGene Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | - | - | - | - | - | |||
| - | ($62M) | - | - | (1.5x) | (1.4x) | |||
| $144M | ($1M) | 1.5x | - | (200.2x) | - | |||
| $19M | ($91M) | - | - | - | - | |||
| $31M | $9M | 4.1x | 2.7x | 14.5x | 10.9x | |||
| - | ($33M) | - | 1.5x | (1.2x) | - | |||
| $65K | ($84M) | 1475.9x | 194.7x | (1.1x) | - | |||
| $172K | ($14M) | 552.2x | 589.9x | (6.9x) | - | |||
This data is available for Pro users. Sign up to see all enGene Therapeutics competitors and their valuation data. Start Free Trial | ||||||||
enGene Therapeutics VC Funding History
Before going public, enGene Therapeutics raised $25M in total equity funding, across 2 rounds.
enGene Therapeutics Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout enGene Therapeutics
| When was enGene Therapeutics founded? | enGene Therapeutics was founded in 2023. |
| Where is enGene Therapeutics headquartered? | enGene Therapeutics is headquartered in Canada. |
| How many employees does enGene Therapeutics have? | As of today, enGene Therapeutics has over 82 employees. |
| Who is the CEO of enGene Therapeutics? | enGene Therapeutics' CEO is Ronald Harold Wilfred Cooper. |
| Is enGene Therapeutics publicly listed? | Yes, enGene Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of enGene Therapeutics? | enGene Therapeutics trades under ENGN ticker. |
| When did enGene Therapeutics go public? | enGene Therapeutics went public in 2023. |
| Who are competitors of enGene Therapeutics? | enGene Therapeutics main competitors include Nyrada, Biomea Fusion, Orient Europharma Co, LENZ Therapeutics, Biosyent, vTv Therapeutics, Inovio Pharmaceuticals, BRIM Biotechnology, Naturland Holding, Tiziana Life Sciences. |
| What is the current market cap of enGene Therapeutics? | enGene Therapeutics' current market cap is $128M. |
| Is enGene Therapeutics profitable? | No, enGene Therapeutics is not profitable. |
| How many companies enGene Therapeutics has acquired to date? | enGene Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies enGene Therapeutics has invested to date? | enGene Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to enGene Therapeutics
Lists including enGene Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




